ABEO - Abeona Therapeutics Inc logo

Abeona Therapeutics Inc

ABEO

Abeona Therapeutics Inc develops gene and cell therapies for serious diseases, particularly focusing on treatments for conditions like recessive dystrophic epidermolysis bullosa, X-linked retinoschisis, stargardt disease, and autosomal dominant optic atrophy.

โš•๏ธ Healthcare NASDAQ Listed 1980 $ USD
$1,000 invested 30 years ago โ†’$0today

Score Overview

1 Year
Score
Net Growth-188.35%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth338.49%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score5.0
Net Growth25.96%
Net Trend40%
Net Income Consistencyโ€”
Rev Growth8x
Rev Trend60%
Revenue Consistencyโ€”
10 Years
Score
Net Growth-187.51%
Net Trend20%
Net Income Consistency
Rev Growth28x
Rev Trend50%
Revenue Consistency
20 Years
Scoreโ€”
Net Growth-388.48%
Net Trend35%
Net Income Consistency
Rev Growthโ€”
Rev Trend58%
Revenue Consistency
30 Years
Score
Net Growth-448.66%
Net Trend40%
Net Income Consistency
Rev Growth152x
Rev Trend59%
Revenue Consistency
All Time
Score
Net Growth-184x
Net Trend39%
Net Income Consistency
Rev Growth8x
Rev Trend57%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Abeona Therapeutics Inc has ranked, year by year

Measure
Fundamentals Window

Showing 10 years ranking history by HDB Score.

Has not reached the top 50 on HDB Score in any year we have ranked.

  • ABEO

2008: 99.1% ยท 2021: 97.9% ยท free through 2021 ยท longest runs

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-22
$ 4.47โ€”
1 Year2025-10-22
$ 5.41-17.38%
5 Years2021-10-22
$ 21.50-79.21%
10 Years2016-10-21
$ 208.50-97.86%
20 Years2006-10-20
$ 1.38K-99.67%
30 Years1996-10-22
$ 132.5K-100.00%
All Time1980-09-19
$ 916.77K-100.00%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 25M-$ 62M$ 146M
2025$ 5M$ 71M$ 191M
2024$ 0.00-$ 63M$ 97M
2023$ 3M-$ 54M$ 52M
2022$ 1M-$ 39M$ 52M
2021$ 3M-$ 84M$ 45M
2020$ 10M-$ 84M$ 95M
2019$ 0.00-$ 76M$ 129M
2018$ 2M-$ 56M$ 84M
2017$ 837K-$ 27M$ 137M
2016$ 889K-$ 21M$ 69M
2015$ 1M-$ 14M$ 40M
2014$ 925K-$ 26M$ 11M
2013$ 2M$ 4M$ 424K
2012$ 4M-$ 10M$ 396K
2011$ 1M-$ 2M$ 2M
2010$ 481K-$ 7M$ 7M
2009$ 352K-$ 17M$ 607K
2008$ 291K-$ 31M$ 2M
2007$ 57K-$ 21M$ 6M
2006-$ 12M$ 4M
2005-$ 1M$ 474K
2004$ 549K-$ 10M$ 2M
2003$ 1M-$ 6M$ 2M
2002$ 1M-$ 9M$ 9M
2001$ 243K-$ 6M$ 20M
2000$ 107K-$ 5M$ 25M
1999$ 15K-$ 3M$ 900K
1998$ 100K-$ 3M$ 1M
1997$ 435K-$ 4M$ 438K
1996$ 167K-$ 11M$ 4M
1995$ 2M$ 341K$ 1M
ABEO - Abeona Therapeutics Inc logo

Abeona Therapeutics Inc fundamental performance

Between 2020 and 2025, revenue declined from $ 10M to $ 5M and net income went from -$ 84M to $ 71M. Revenue increased in 3 of those 5 years; net income in 2.

Between 1995 and 2025, revenue grew from $ 2M to $ 5M and net income grew from $ 341K to $ 71M. Revenue increased in 18 of those 30 years; net income in 12.

Abeona Therapeutics Inc currently holds a 5-year HDB Score of 5.0 out of 10. How the HDB Score is calculated.

Membership

Continue ABEOโ€™s history

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,119 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies